Medscape5h
Despite Price Caps, Some Still Struggle to Access Insulin
While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...
Monthly Prescribing Reference22h
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.
Managed Healthcare Executive1h
FDA Approves First Biosimilar of Novolog
Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
drugdeliverybusiness23h
Medtronic seeks to expand MiniMed 780G label to type 2 diabetes, submits new CGM to FDA
Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...
Hosted on MSN16h
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...
SHINE5h
China developed diabetes drug highlights biopharma surge
Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...
Alabama Poison Information Center sees alarming trend with children accidentally using GLP-1 medications
The Alabama Poison Information Center has seen an increase in calls relating to children accidentally exposing themselves to ...
Injectable Drug Delivery Devices Market Size Expected To Reach USD 1,217 Bn By 2034
The global injectable drug delivery devices market size is calculated at USD 565 billion in 2025 and is expected to reach around USD 1,217 billion by ...